Figure 7
Effects of a combination of WCE with docetaxel on hormone-refractory prostate cancer. (a) Dose-response curves of PC-3 and DU145 cells following treatment with different concentrations of docetaxel alone or plus 10 μmol/L of luteolin, apigenin or wedelolactone. (b) WCE-mediated suppression effect on docetaxel (30 nM)-induced IKK phosphorylation and its downstream molecules were analyzed using western blot. L, luteolin 10 μmol/L. A, apigenin 10 μmol/L. W, wedelolactone 10 μmol/L. (c) Tumor growth curves were determined by measuring BLI intensity weekly following the indicated treatments of the vehicle, 30 mg/kg WCE, 10 mg/kg docetaxel or a combination. Bottom, longitudinal BLI images of representative mice in each group. (d) Cytokeratin-18 staining to detect PC-3 cells in primary tumors following indicated treatments. Scale bar, 50 μm. (e) The longitudinal mouse body weight in each group was plotted against time after treatment. (f) The systemic toxicity of different treatment was analyzed by measuring BUN (blood urea nitrogen), GOT (glutamic-pyruvic transaminase), and GPT (glutamic-oaa transaminase) in the plasma. (g,h) Pathological analyses of the liver (g) and kidney (h) tissues were examined by H&E staining. Pv, hepatic portal vein. The area of necrosis is enclosed by the dotted line. Arrow, necrotic tissue. Arrow, mesangial expansion. Scale bar, 50 μm. Data are expressed as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by unpaired Student’s t-test.
